Recurrent head and neck cancer: Current treatment and future prospects

Expert Review of Anticancer Therapy

Volumn 8, Issue 3, 2008, Pages 375-391

  Specenier, Pol M ^a   Vermorken, Jan B ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Chemotherapy; EGFR; Head and neck cancer; Metastatic disease; Palliative treatment; Recurrent disease; Targeted therapies

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IMC 225; IRINOTECAN; LAPATINIB; LONAFARNIB; MATUZUMAB; MESNA; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PEMETREXED; PLACEBO; PLATINUM COMPLEX; UNINDEXED DRUG; VINCRISTINE;

ANEMIA; AREA UNDER THE CURVE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPHAGIA; FATIGUE; FEBRILE NEUTROPENIA; FOLLICULITIS; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEAD AND NECK CARCINOMA; HUMAN; HYPOKALEMIA; HYPONATREMIA; INFECTION; LIVER TOXICITY; LOADING DRUG DOSE; LUNG TOXICITY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PARESTHESIA; PREDICTION; RECURRENT CANCER; REVIEW; SEPSIS; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; SYSTEMIC DISEASE; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; FORECASTING; HEAD AND NECK NEOPLASMS; HUMANS; METHOTREXATE; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; SALVAGE THERAPY;

EID: 45249102629     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.3.375     Document Type: Review

References (192)

1. Vermorken JB. Medical treatment in head and neck cancer. Ann. Oncol. 16 (Suppl. 2), ii258-ii264 (2005).
2. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 24(17), 2644-2652 (2006).
3. Grose WE, Lehane DE, Dixon DO, Fletcher WS, Stuckey WJ. Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a Southwest Oncology Group Study. Cancer Treat. Rep. 69(6), 577-581 (1985).
4. Hong WK, Schaefer S, Issell B et al. A prospective randomized trial of methotrexate vs cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer 52(2), 206-210 (1983).
5. Vermorken JB, Catimel G, de Mulder P et al. Randomized Phase II trial of weekly methotrexate vs two schedulès of three-weekly paclitaxel in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Proc. Amer. Soc. Clin. Oncol. 18, 395a (1999) (Abstract 1527).
6. Tahara M, Minami H, Hasegawa A et al. Early Phase II study of weekly paclitaxel as a one hour infusion in patients with recurrent or metastatic head and neck cancer. American Association for Cancer Research Meeting Abstract. (2007) (Abstract 3526).
7. Hitt R, Amador ML, Quintela-Fandino M et al. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer 106(l), 106-111 (2006).
8. Guardiola E, Peyrade F, Caigneau L et al. Results of a randomized Phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur. J. Cancer 40(14), 2071-2076 (2004).
9. Vogl SE, Schoenfeld DA, Kaplan BH, Lerner HJ, Engstrom PF, Horton J. A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer. Cancer 56(l), 432-442 (1985).
10. Chauvergne J, Cappelaere P, Fargeot P et al. A randomized study comparing cisplatin alone or combined in the palliative treatment of carcinoma of the head and neck. Analysis of a series of 209 patients. Bull. Cancer 75(1), 9-22 (1988).
11. Clavel M, Cognetti F, Dodion P et al. Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck. Cancer 60(6), 1173-1177 (1987).
12. Clavel M, Vermorken JB, Cognetti F et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) vs cisplatin and 5-fluorouracil (CF) vs cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A Phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann. Oncol. 5(6), 521-526 (1994).
13. No authors listed. A Phase III randomized trial of cisplatin, metotrexate, cisplatin + metotrexate and cisplatin + 5FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. Br. J. Cancer 61(2), 311-315 (1990).
14. Forastiere AA, Metch B, Schuller DE et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil vs methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J. Clin. Oncol. 10(8), 1245-1251 (1992).
15. 'De Andres L, Brunet J, Lopez-Pousa A et al. Randomized trial of neoadjuvant cisplatin and fluorouracil vs carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J. Clin. Oncol. 13(6), 1493-1500 (1995).
16. Eisenberger M, Krasnow S, Ellenberg S et al. A comparison of carbo platin plus methotrexate vs methotrexate alone in patients with recurrent and metastatic head and neck cancer. J. Clin. Oncol. 7(9), 1341-1345 (1989).
17. Jacobs C, Lyman G, Velez-García E. et al. A Phage III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin. Oncol. 10(2), 257-263 (1992).
18. Lorusso V, Calvi N, Ciccarese M et al. Phase II study of capecitabine with cisplatin in advanced head and neck cancer: preliminary results. J. Clin. Oncol. 25(18S), (2007) (Abstract 16502).
19. Gil-Negrete A, Mae JM, Ruiz de Lobera A et al. First-line docetaxel and capecitabine in advanced head and neck cancer. J. Clin. Oncol. 25(18S), (2007) (Abstract 16505).
20. Bentzen JD, Hansen HS. Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region. Head Neck 29(1), 47-51 (2007).
21. Samlowski WE, Moon J, Kuebler JP et al. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Invest. 25(3), 182-188 (2007).
22. Guntinas-Lichius O, Appenrodt S, Veelken F, Krug B. Phase II study of weekly docetaxel and cisptatin in patients with advanced recurrent and metastatic head and neck cancer. Laryngoscope 116(4), 613-618 (2006).
23. Gibson MK, Li Y, Murphy B et al. Randomized Phase III evaluation of cisplatin plus fluorouracil vs cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 23(15), 3562-3567 (2005).
24. Fountzilas G, Papakostas P, Dafni U et al. Paclitaxel and gemcitabine vs paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. Ann. Oncol. 17(10), 1560-1570 (2006).
25. Raguse JD, Gath HJ, Oettle H, Bier J. Oxaliplatin, folinic acid and 5-fluorouracil (OFF) in patients with recurrent advanced head and neck cancer: a Phase II feasibility study. Oral. Oncol. 42(6), 614-618 (2006).
26. Labourey JL, Cupissol D, Calais G et al. Docetaxel plus gemcitabine in recurrent and/or metastatic squamous us cell carcinoma of the head and neck: a Phase II multicenter study. Am. J. Clin. Oncol. 30(3), 278-282 (2007).
27. Xydakis E, Repassos E, Poulou M et al. Second line chemotherapy with methotrexate and gemcitabine in patients with relapsing head and neck cancer. J. BUON 11(4), 419-424 (2006).
28. Specenier P, Vermorken JB. Neoadjuvant chemotherapy in head and neck cancer Should it be revisited? Cancer Lett. 256(2), 166-177 (2007).
29. Hitt R, Lopez-Pousa A, Martinez-Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J. Clin. Oncol. 23(34), 8636-8645 (2005).
30. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med. 357(17), 1705-1715 (2007).
31. Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancell N. Engl. J. Med. 357(17), 1695-1704 (2007).
32. Janinis J, Papadakou M, Xidakis E et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a Phase II feasibility study. Am. J. Clin. Oncol. 23(2), 128-131 (2000).
33. Benasso M, Ponzanelli A, Merlano M et al. Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a Phase II trial from an Italian cooperative group. Acta Oncol. 45 (2), 168-174 (2006).
34. Shin DM, Glisson BS, Khuri FR et al. Phase II trial of paclitaxel, ifosfamide and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16(4), 1325-1330 (1998).
35. Shin DM, Khuri FR, Glisson BS et al. Phase II study of paclitaxel, ifosfamide and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 91(7), 1316-1323 (2001).
36. Zhang P, Zhang Z, Zhou X, Qiu W, Chen F, Chen W. Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line. BMC Cancer 6, 224 (2006).
37. Frederico MH, Brunialti KC, Castro G et al. Gluthatione-S-transferase genes polymorphisms predict response and progression free survival in head and neck cancer patients treated with cisplatin based chemoradiotherapy. J. Clin. Oncol. 25 (18S), (2007) (Abstract 21127).
38. Guo Z, Chen Z, Yang Z, Schumaker L, Cullen KJ. Promotor hypermethylation of GPX3 as a predictor for chemoresistance and survival in head and neck cancer patients. J. Clin. Oncol. 25(18S), (2007) (Abstract 6027).
39. Le Tourneau C, Fau-ivre S, Siu LL. Molecular targeted therapy of head and neck cancer: review and clinical development challenges. Eur. J. Cancer 43(17), 2457-2466 (2007).
40. Specenier P, Vermorken JB. Targeted therapies in head and neck cancer. Target. Oncol. 2(2), 73-78 (2007).
41. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor receptor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 53(15), 3579-3584 (1993).
42. Chung CH, Ely K, McGavran L et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J. Clin. Oncol. 24(15), 4170-4176 (2006).
43. Mrhalova M, Plzak J, Betka J et al. Epidermal growth factor receptor - its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas. Neoplasma 52(4), 338-343 (2005).
44. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur. J. Cancer 37 (Suppl. 4) S9-S15 (2001).
45. Ang KK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 62(24), 7350-7356 (2002).
46. Grandis JR, Melhem MF, Gooding WE et al. Levels of TGFα and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst. 90(11), 824-832 (1998).
47. Grandis JR. Prognostic biomarkers in head and neck cancer. Clin. Cancer Res. 12(17), 5006-5006 (2006).
48. Dassonville O, Formento JL, Francoul M et al. (1993) Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J. Clin. Oncol. 11(10), 1873-1878 (1993).
49. Maurizi M, Almadori G, Ferrandina G et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br. J. Cancer. 74(8), 1253-1257 (1996).
50. Smid EJ, Stoter TR, Bloemena E et al. The importance of immunohistochemical expression of EGFR in squamous cell carcinoma of the oral cavity treated with surgery and postoperative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 65(5), 1323-1329 (2006).
51. El-Rayes BF, LoRusso PM. Targeting the epidermal growth factor receptor Br. J. Cancer 91(3), 418-424 (2004).
52. Marshall L. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107(6), 1207-1218 (2006).
53. Modjtahedi H. Molecular therapy of head and neck cancer. Cancer Metastasis Rev. 24(1), 129-145 (2006).
54. Choong NW, Cohen EEW. Epidermal growth factor receptor directed therapy in head and neck cancer. Crit. Rev. Oncol. Hematol. 57(1), 25-43 (2006).
55. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 23(11), 2445-2459 (2005).
56. Cohen EEW. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 24(17), 2659-2665 (2006).
57. Baselga J, Trigo JM, Bourhis J et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23(24), 5568-5577(2005).
58. Herbst RS, Arquette M, Shin DM et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23(24), 5578-5587 (2005).
59. Vermorken JB, Trigo J, Hitt P et al. Open-label, uncontrolled, multicenter Phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol. 25 (16), 2171-2177(2007).
60. Leon X, Hitt R, Constenla M et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin. Oncol. (R. Coll Radiol) 17(6), 418-424 (2005).
61. Fan Z, Baselga J, Masui H et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 53(19), 4637-4642 (1993).
62. Bourhis J, Rivera F, Mesia. R et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 24(18), 2866-2872 (2006).
63. Burtness B, Goldwasser M, Flood W et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recuirent head and neck cancer: an Eastern Cooperative Oncology Group Study. J. Clin. Oncol. 23(34), 8646-8654 (2005).
64. Vermorken JB, Mesia R, Veg-Villegas ME et al. Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME). J. Clin. Oncol. 24(18S), 289s (2006) (Abstract 5537).
65. Vermorken JB, Mesia R, Vega-Villegas ME et al. Cetuximab extends survival of patients with recurrent and/or metastatic squamouscelle carcinoma of the head and neck when added to first line platinum based therapy. Results of a randomized Phase III trial (EXTREME). J. Clin. Oncol. 2518S), 6091 (2007) (Abstract).
66. Vermorken JB, Hitt R, Geoffrois L et al. Cetuximab plus platinum-based therapy first-line in recurrent and/or metastatic squamous cell carcinoma of the head and neck: efficacy and safety results of a randomized Phase III trial (EXTREME). Eur. J. Cancer 4354 Suppl.), 321 (2007) (Abstract 5501).
67. Bier H, Hoffman T, Hauser U et al, Clinical trial with escalating doses of the antiepidermial growth factor receptor humanized monoclonal antibody EMD72000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother. Pharmacol. 47(6), 519-524 (2001).
68. Vanhoefer U, Tewes M, Rojo F et al Phase I study of the humanized antiepidermal growth factor receptor monoconal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol. 22(1), 175-184 (2004).
69. Salazar R, Tabarnero J, Rojo F et al. Dose-dependent inhibition of the EGFR and signalling pathways with the EGFR monoclonal antibody EMD 72000 administered everg three weeks. A Phase I pharmacokinetic/ pharmacodynamic study to define the optimal biological dose. J. Clin. Oncol. 22(14S), 127 (2004) (Abstract 2002).
70. Foon KA, Yang XD, Weiner LM et al, Preclinical and clinical evaluations of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody. Int. J. Radiat Oncol. Biol. Phys. 58(3), 984-990 (2004).
71. Winquist E, Nabid A, Sicheri D et al. A Phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy (RT). Proc. Am. Soc. Clin. Oncol. 21, (2002) (Abstract 926).
72. Crombet T, Osorio M, Cruz T et al. Use of the anti-EGFR antibody h-R3 in combination with radiotherapy in the treatment of advanced head and neck cancer. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. Proc. Am. Soc. Clin. Oncol. 21, 14a (2002) (Abstract 53).
73. Bastholt L, Specht L, Jensen K et al. A novel fully human monoclonal antibody against epidermal growth factor receptor (EGFR). First clinical and FDG-PET imaging results from a Phase I/II trial conducted by the Danish Head and Neck Cancer Study Group (DAHANCA) in patients with squamous cell carcinoma of the head and neck (SCCHN). J. Clin, Oncol. 23(16S), 507s (2005) (Abstract 5530).
74. Cohen EEW. Rosen F, Stadler WM et al. Phase II trial of ZD 1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 21 (10), 1980-1987 (2003).
75. Kirby AM, A'Hern RP, D'Ambrosio C et al. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br. J. Cancer 94(5), 631-636 (2006).
76. Wheeler RH, Jones D, Sharma P et al. Clinical and molecular Phase II study of gefitinib in patients with recurrent squamous cell cancer of the head and neck J. Clin. Oncol. 23(16S), 507s (2005) (Abstract 5531).
77. Cohen EE, Kane MA, List MA et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin. Cancer Res. 11(23), 8418-8424 (2005).
78. Stewart JSW, Cohen EEW, Licitra L et al. A Phase III randomized parallel-group study of gefitinib vs methotrexate in patients with recurrent squamous cell carcinoma of the head and neck. American Association for Cancer Research Meeting Abstracts (2007) (Abstract 3522).
79. Soulieres D, Senzer NN, Vokes EE et al. Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 22(1), 77-85 (2004).
80. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III Trial - INTACT 1. J. Clin. Oncol. 22(5), 777-784 (2004).
81. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 22(5), 785-794 (2004).
82. Siu LL, Soulieres D, Chen EX et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital Phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J. Clin. Oncol. 25(16), 2178-2183 (2007).
83. Belon J, Irigoyen, A, Rodriguez I et al. Preliminary results of a Phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck. J. Clin. Oncol. 23(16S), 515s (Abstract 5563) (2005).
84. Huang S, Armstrong EA, Benavente S et al. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 64(15), 5355-5362 (2004).
85. Matar P, Rojo F, Cassia R et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal atibody cetuximab (IMC-225); superiority over single-agent receptor targeting. Clin. Cancer Res. 10(19), 6487-6501 (2004).
86. Agulnik M, da Cunha Santos G, Hedley D et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J. Clin. Oncol. 25(16), 2184-2190 (2007).
87. Sok JC, Coppelli FM, Thomas SM et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin. Cancer Res. 12(7), 5064-5073 (2006).
88. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497-1500 (2004).
89. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
90. Mukohara T, Engelman JA. Hanna N et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancer cell lines bearing epidermal growth factor receptor mutation. J. Natl. Cancer Inst. 97(16), 1185-1194 (2005).
91. Guo M, Liu S, Herman JG et al. Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450. Cancer Biol, Ther. 5(2), 152-155 (2006).
92. Guo M, Liu S, Lu F. Gefitinib-sensitizing mutations in esophageal carcinoma. N. Engl. J. Med. 354(20), 2193-2194 (2006).
93. Lee JW, Soung YH, Kim SY et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 11(8), 2879-2882 (2005).
94. Willmore-Payne C, Holden JA, Layfield LJ. Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Mod. Pathol. 19(5), 634-640 (2006).
95. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur. J. Cancer 42(1), 109-111 (2006).
96. Cohen EE, Lingen MW, Martin LE et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin. Cancer Res. 11(22), 8105-8108 (2005).
97. Delord J, Thomas F, Benlyazid A et al. Neo-adjuvant treatment with erlotinb in squamous cell carcinoma head and neck (SCCHN) patients before surgery provides an opportunity to find predictive factors of response. J. Clin. Oncol. 24(18S), 283s (2006) (Abstract 5513).
98. Mojica WD, Khoury T, Starostik P, Cheney RT. Frequency of gefitinib responder mutations in EGFR (+) squamous cell carcinoma of the head and neck. American Association for Cancer Research Meeting Abstract 992-993 (2005).
99. Na I, Kang H, Park Y et al. EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. J. Clin. Oncol. 24(18S), 547s (2006) (Abstract 10027).
100. Murray S, Linardou H, Razis E, Pectasidis D, Fountzilas G. Screening for EGFR mutations in patients with head and neck cancer treated with gefitinib on a compassionate-use program: a Hellenic Cooperative Oncology Group study. Ann. Oncol. 17 (Suppl. 9), ix180 (2006) (Abstract 578).
101. Xia W, Lau YK, Zhang HZ et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin. Cancer Res. 5(12), 4164-4174 (1999).
102. Gillison ML, Glisson BS, O'Leary E et al. Phase II trial of trastuzumab (T), paclitaxel (P), and cisplatin (C) in metastatic (M) or recurrent (R) head and neck squamous cell carcinoma (HNSCC): response by tumor EGFR and HER2/neu status. J. Clin. Oncol. 24(18S), 282s 5511 (Abstract) (2006).
103. Abidoye OO, Cohen EE, Wong SJ et al. A Phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol. 24(18S), 297s (2006) (Abstract 5568).
104. Cruz JJ, Ocana A, Del Barco E, Pandiella A. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Ann. Oncol. 18(3), 421-430 (2007).
105. Gupta AK, McKenna WG, Weber CN et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin. Cancer Res. 8(3), 885-892 (2002).
106. Massarelli E, Liu DD, Lee JJ et al. Akt activation correlates with adverse outcome in tongue cancer. Cancer. 104(11), 2430-2436 (2005).
107. Argiris A, Cohen E, Karrison T et al. A Phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol. Ther. 5(7), 766-770 (2006).
108. Schmelzle T, Hall MN. Tor, a central controller of cell growth. Cell103(2), 253-262 (2000).
109. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 124(3), 471-484 (2006).
110. Aissat N, Le Tourneau C, Ghoul A et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother. Pharmacol. (2007) (Epub ahead of print).
111. Amornphimoltham P, Patel V, Sodhi A et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res. 65(21), 9953-9961 (2005).
112. Perootti A, Maur M, Vigano L et al. Phase Ib pharmacokinetic (PK) and pharmacodynamic (PD) study to define the optimal dose for combining the mTOR inhibitor AP23573 with capecitabine (CAPE). J. Clin. Oncol. 24(18S), 137s (2006) (Abstract 3065).
113. Raymond E, Alexandre J, Faivre S et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. 22(12), 2336-2347 (2004).
114. Chun K-H, Lee H-Y, Hassan K, Khuri F, Hong WK, Lotan R. Implication of protein kinase B/Akt and Bcl-2Bcl-Xl suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cell. Cancer Res. 63(16), 4796-4800 (2003).
115. Ren H, Tai S-K, Khuri F Chu Z, Mao L. Farnesyltransferase inhibitor SCH66336 induces rapid phophorylation of eukaryotic translation prolongation factor 2 in head and neck squamous carcinoma cells. Cancer Res. 65(13), 5841-5846 (2005).
116. Oh SH, Kim WY, Kim JH et al. Identification of insulin-like growth factor binding protein-3 as a farnesyltransferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin. Cancer Res. 12(2), 653-661 (2006).
117. Kies MS, Clayman GL, El-Naggar AK et al. Induction therapy with SCH 66336, a farnesyltransferase inhibitor, in squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol. 20, 225a (2001) (Abstract 896).
118. Yang CH, Kies MS, Glisson B et al. A Phase II study of lonafarnib (SCH66336) in patients with chemo-refractory advanced head and neck squamous cell carcinoma (HNSCC). J. Clin. Oncol. 23(16S), 516s (2005) (Abstract 5565).
119. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal kinase or Akt kinase pathways. Clin. Cancer Res. 9(6), 2316-2326 (2003).
120. Mantha AJ, McFee KE, Niknejad N, Goss G, Lorimer IA, Dimitroulakos J. Epidermal growth factor-receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells. J. Cancer Res. Clin. Oncol. 129(11), 631-641 (2003).
121. Buck E, Eyzaguirre A, Brown E et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small cell lung, pancreatic, colon and breast tumors. Mol. Cancer Ther. 5(11), 2676-2684 (2006).
122. Gallo O, Masini E, Bianchi B et al. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum. Pathol. 33(7), 708-714 (2002).
123. Peng J, Su C, Chang H. Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx. Hum. Pathol. 33(1), 100-104 (2002).
124. Lin D, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 24(8), 792-799 (2002).
125. Itoh S, Matsui K, Furuta I, Takano Y. Immunohistochemical study of overespression of cyclooxygenase-2 in squamous cell carcinoma of the oral cavity: its importance as a prognostic predictor. Oral. Oncol. 39(8), 829-835 (2003).
126. Renkonen J, Wolff, Paavonen T. Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Arch. 440(6), 594-597 (2002).
127. Pannone G, Bufo P, Caiaffa MF et al. Cyclooxygenase-2 expression in oral squamous cell carcinoma. Int. J. Immunopathol. Pharmacol. 17(3), 373-382 (2004).
128. Chan G, Boyle JO, Yang EY et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 59(5), 991-994 (1999).
129. Grau JJ, Monzo JC, Palmero R et al. Expression of cyclooxygenase-2 mRNA in peripheral blood of head and neck cancer patents and healthy controls. J. Clin. Oncol. 22(14 S), 491 (2004) (Abstract 5521).
130. Lippman SM, Gibson N, Subbaramaiah K, Dannenberg AJ. Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clin. Cancer Res. 11(17), 6097-6099 (2005).
131. Choe MS, Zhang X, Chin JC et al. Interaction between epidermal growth factor receptor-and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol. Cancer Ther. 4(17), 1448-1455 (2005).
132. Wirth LJ, Haddad RI, Lindeman NI et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23(28), 6976-6981 (2005).
133. Kyzas PA, Cunha IW, Ioannidis JPA. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin. Cancer Res. 11(4), 1434-1440 (2005).
134. Kyzas AP, Stefanou D, Batistou A, Agnatis NJ. Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 131(9), 624-630 (2005).
135. Mauer AM, Cohen EEW, Wong SJ et al. Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol. 22(14S), 496 (2004) (Abstract 5539).
136. Seiwert TY, Davis DW, Yan D et al. pKDR/KDR ratio predicts response in a Phase I/II pharmacodynamic study of erlotinib and bevacizumab for recurrent or metastatic head and neck cancer. J. Clin. Oncol. 25 (18S), 304s (2007) (Abstracr 6021).
137. Karamouzis MV, Friedland D, Johnson R, Rajasenan K, Branstetter B, Argiris A. Phase II trial of pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): an interim analysis. J. Clin. Oncol. 25(18S), (2007) (Abstract 6049).
138. Fury MG, Zahalsky A, Wong R et al. A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest. New Drugs 25(2), 165-172 (2007).
139. Cooney MM, Tserng KY, Makar V et al. A Phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. Cancer Chemother. Pharmacol, 55(3), 295-300 (2005).
140. Elser C, Siu LL, Winquist E et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J. Clin. Oncol. 25(24), 3766-3773 (2007).
141. Williamson SK, Moon J, Huang CH, Guaglianone P, Wolf GT, Urba SG. A Phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): a Southwest Oncology Group (SWOG) trial. J. Clin. Oncol. 25(18S), 310s (2007) (Abstract 6044).
142. Sano D, Kawakami M, Fujita K et al. Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncol. Rep. 17, 289-295 (2007).
143. Heymach JV, Johnson BE, Prager D et al. Randomized, placebo-controlled Phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J. Clin. Oncol. 25(27), 4270-4277 (2007).
144. Mitsiades CS, Mitsiades N, McMullan CJ et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other haematologic malignancies, and solid tumors. Cancer Cell 5(3), 221-230 (2004).
145. Barnes C, Kumar R. Insulin-like growth factor receptor 1 as a therapeutic target in head and neck cancer. American Association for Cancer Research Meeting Abstract (2005) (Abstract 1191).
146. Garcia-Ecchevaria C, Pearson MA, Martia et al. In vivo antitumor activity of NVP-AEW541 - a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5(3), 231-239 (2004).
147. Wang Y, Hailey J, Williams D et al Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol. Cancer Ther. 4(8), 1214-1221 (2005).
148. Haluska P, Carboni JM, Loegering DA et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/ insulin receptor inhibitor, BMS-554417. Cancer Res. 66(1), 362-371 (2006).
149. Karp DD, Paz-Ares LG, Blakely LJ et al. Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 25(18S), 386s (2007) (Abstract 7506).
150. Siesser PM, Hanks SK. The signaling and biological implications of FAK overexpression in cancer. Clin. Cancer Res. 12(11 Pt 1), 3233-3237 (2006).
151. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin. Cancer Res. 11(19 Pt 1), 6924-6932 (2005).
152. Han H, Von Hoff DD. Aurora sheds light on head and neck squamous cell carcinoma. Clin. Cancer Res. 12(17), 5003-5004 (2006).
153. Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 66(11), 5542-5548 (2006).
154. Canel M, Secades P, Rodrigo JP et al. Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number. Clin. Cancer Res. 12 (11 Pt 1), 3272-3279 (2006).
155. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Cancer Clin. Res. 9(17), 6316-6325 (2003).
156. Voorhees PM, Orlowski RZ. The proteasome inhibitors in cancer therapy. Annu. Rev. Pharmacol. Toxicol. 46, 189-213 (2006).
157. Russo SM, Tepper JE, Baldwin AS Jr, Enhancement of radiosensivity by proteasome inhibition: implications for a role of NF-κB. Int. J. Radiat. Oncol. Biol. Phys. 50(1), 183-193 (2001).
158. Ricker J, Lee TL, Chen Z, Van Waes C. Bortezomib (VELCADE TM), formerly known as PS-341 in combination with cisplatin or paclitaxel in head and neck squamous cell carcinoma. American Association for Cancer Research Meeting Abstract (2004) (Abstract 1064).
159. Lorch JH, Thomas TO, Schmoll HJ. Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death squamous cell cancer. Cancer Res. 67(2), 727-734 (2007).
160. Weber CN, Cerniglia GJ, Maity A, Gupta AK. Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation. Cancer Biol. Ther. 6(2), 156-159 (2007).
161. Chung V, Zhou B, Liu X et al. SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone. Mol. Cancer Ther. 5(3), 533-540 (2006).
162. Van Wies C, Chang A, Lebowitz P et al. Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent Head- and-neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 63(5), 1400-1412 (2005).
163. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J. Cell Biochem. 96(2), 293-304 (2005).
164. O'Connor OA. Targeting histones and proteasomes: new strategies for the treatment of lymphoma. J Clin. Oncol. 23(26), 6429-6436 (2005).
165. Erlich RB, Guminski R, Rickwood D, Saunders N. Valproic acid as a therapeutic agent for head and neck squamous cell carcinoma. American Association for Cancer Research Meeting Abstract (2007) (Abstract 680).
166. Bruzzese F, Di Gennaro E, Budillon A. Synergistic antitumor effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in combination with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in squamous-cell carcinoma of the head and neck derived cell lines. American Association for Cancer Research Meeting Abstract 1299-1300 (2004).
167. Shen J, Huang C, Jiang L et al. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem. Pharmacol. 73(12) 1901-1909 (2007).
168. Kelly WK, O'Connor OA, Krug ML et al. Phase I Study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23(17), 3923-3931 (2005).
169. Tang P, Oza A, Townsley C et al. A Phase I study of vorinostat in combination with capecitabine in patients with advanced solid tumors. J. Clin. Oncol. 25(18S), (2007) (Abstract 3576).
170. Blumenschein G, Lu C, Kies M et al. Phase II clinical trial of suberoylanilide hydroxamic acid (SAHA) in patients (pts) with recurrent and/or metastatic head and neck cancer (SCCHN). J. Clin. Oncol. 22(14S), 505 (2004) (Abstract 5578).
171. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24(11), 1770-1783 (2006).
172. Patel V, Senderowicz AM, Pinto D Jr et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J. Clin. Invest. 102(9), 1674-1681 (1998).
173. Mihara M, Shintani S, Kiyota A, Matsumura T, Wong DT. Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells. Int. J. Oncol. 21(1), 95-101 (2002).
174. Otsubo A, Bhawal UK, Nomura Y et al. UCN-01 (7-hydroxystaurosporine) induces apoptosis and G1 arrest of both primary and metastatic oral cancer cell lines in vitro. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 103(3), 391-397 (2007).
175. Patel V, Lahusen T, Leethanakul C et al. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1). Clin. Cancer Res. 8(11), 3549-3560 (2002).
176. Caponigro F, Basile M, de Rosa V, Normanno N. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004. Anticancer Drugs 16(2), 211-221 (2005).
177. Teicher BA. Protein kinase C as a therapeutic target. Clin. Cancer Res. 12(18), 5336-5345 (2006).
178. Cohen EE, Lingen MW, Zhu B et al. Protein kinase Cζ mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase. Cancer Res. 66(12), 6296-6303 (2006).
179. Hoffmann TK, Leenen K, Hafner D et al. Antitumor activity of protein kinase C inhibitors and cisplatin in human head and neck squamous cell carcinoma lines. Anticancer Drugs 13(1), 93-100 (2002).
180. Chmura SJ, Dolan ME, Cha A, Mauceri HJ, Kufe DW, Weichselbaum RR. In vitro and in vivo activity of protein kinase C inhibitor chelethyrine chloride induces tumor cell toxicity and growth delay in vivo. Clin. Cancer Res. 6(2), 737-742 (2000).
181. Rademaker-Lakhai JM, Beerepoot LV, Mehra N et al. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase Cβ-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin. Cancer Res. 13(15 Pt 1), 4474-4481 (2007).
182. Tatsuka M, Sato S, Kitajima S et al. Overexpression of Aurom-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene 24(6), 1122-1127 (2005).
183. Wang XX, Liu R, Jin SQ, Fan FY, Zhan QM. Overexpression of Aurora-A kinase promotes tumor cell proliferation and inhibits apoptosis in esophageal squamous cell carcinoma cell line. Cell Res. 16(4), 356-366 (2006).
184. Reiter R, Gais P, Jütting U et al. Aurora kinase A messenger RNA overexpression is correlated with tumor-progression and shortened survival in head and neck squamous cell carcinoma. Clin. Cancer Res. 12(17), 5136-5141 (2006).
185. Tanaka E, Hashimoto Y, Ito T et al. The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma. Clin. Cancer Res. 11(5), 1827-1834 (2005).
186. Schellens JH, Boss D, Witteveen PO et al. Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152. J. Clin. Oncol. 24(18S), (2006) (Abstract 3008).
187. Gakvin KM, Huck J, Burenkova O et al. Preclinical pharmacodynamic studies of Aurora A inhibition by MLN8054. J Clin. Oncol. 24(18S), 606s (2006) (Abstract 13059).
188. Plyte S, Musacchio A. PLK1 inhibitors: setting the mitotic death trap. Curr. Biol. 17(8), R280-R283 (2007).
189. Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res. 59(12), 2794-2797 (1999).
190. Takagi M, Honmura T, Watanabe S et al. In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-l76. Invest. New Drugs 21(4), 387-399 (2003).
191. Steegmaier M, Hoffmann M, Baum A et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr. Biol. 17(4), 316-322 (2007).
192. Kawecki A, Adkins DR, Cunningham CC et al. A Phase II study of ARQ 501 in patients with advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol. 25(18S), 669s (2007) (Abstract 16509).